Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nasreen Khalil, Helene Manganas, Christopher J. Ryerson, Shane Shapera, Andre M. Cantin, Paul Hernandez, Eric E. Turcotte, Joseph M. Parker, John E. Moran, Gary R. Albert, Renata Sawtell, Aline Hagerimana, Pierre Laurin, Lyne Gagnon, Frank Cesari, Martin Kolb. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018

Member's Comments

No comment yet.

Related content which might interest you: Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018 Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013 The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2017 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014